Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRTB-HDT trial of adjunctive host-directed therapies in rifampin-resistant tuberculosis
2020-004295-18Phase 2Active
- Sponsor
- Aurum Institute
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dovramilast and metformin in Rifampicin-resistant pulmonary tuberculosis (RR-PTB) and pulmonary tuberculosis (TB) (3 arms), sponsored by Aurum Institute. Primary endpoints: Co-primary endpoints (1) and Co-primary endpoints (2). Started Jan 2025; status: active.
02
Drugs
dovramilastmetformin
03
Conditions
Rifampicin-resistant pulmonary tuberculosis (RR-PTB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2020-004295-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004295-18.